RxDoctor Payments Data

Peter Obesso, DO

Sleep Medicine · Tyler, TXNPI 1356577787

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $22,586 of the $33,971 with a category attached, or 66.5%. 15 manufacturers reported payments, led by Idorsia Pharmaceuticals US Inc at 56.9% of the total. Reporting peaked in 2023 at $11,060 and has fallen 61.4% since, to $4,273 in 2025. Among sleep medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$33,971in general payments, 2019–2025

Across 251 payments — averaging $135.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Idorsia Pharmaceuticals US Inc$19K
  • Axsome Therapeutics, Inc.$7K
  • ZOLL Respicardia, Inc.$3K
  • Inspire Medical Systems, Inc.$2K
  • Jazz Pharmaceuticals Inc.$1K
  • Harmony Biosciences LLC$826
  • plus $632 from 9 others

What the payments were for

  • Consulting fees$1,9136%
  • Speaking & faculty fees$22,58666%
  • Travel & lodging$2,9509%
  • Food & beverage$6,01018%
  • Education$5112%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,971 in reported general payments places this provider in the 90th percentile of 112 sleep medicine providers in Texas.

See all sleep medicine providers in Texas

Medicare billing

Part B allowed, 2024
$120,223
Medicare patients
786
Services billed
1,483

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelsomraSuvorexant37$18,451
DayvigoLemborexant24$10,467
Modafinil23$8,298
Armodafinil13$1,351
Temazepam88$1,212
Ropinirole Hcl77$1,209
Doxepin Hcl19$889
Zolpidem Tartrate113$809
Prazosin Hcl19$720
Pramipexole DihydrochloridePramipexole Di-Hcl33$637
Eszopiclone50$511
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine17$501
Clonazepam36$438
Gabapentin25$370
Zaleplon17$179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckBelsomra$235$18,45137 claims
Eisai Inc.Dayvigo$125$10,46724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 112 sleep medicine providers in Texas.

Other sleep medicine in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →